Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32534646

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2020 Jun 13
First author
Gutzmer R

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2020 Jun 13;395(10240):1814-1815. doi: 10.1016/S0140-6736(20)31285-X.
    note
    Source null
    related pmid
    32534635
    relationship
    Comment in
  2. citation
    Lancet. 2020 Aug 15;396(10249):466. doi: 10.1016/S0140-6736(20)31721-9.
    note
    Source null
    related pmid
    32798490
    relationship
    Erratum in

Authors and identifiers

  1. name
    Gutzmer R
    type
    Author
  2. name
    Stroyakovskiy D
    type
    Author
  3. name
    Gogas H
    type
    Author
  4. name
    Robert C
    type
    Author
  5. name
    Lewis K
    type
    Author
  6. name
    Protsenko S
    type
    Author
  7. name
    Pereira RP
    type
    Author
  8. name
    Eigentler T
    type
    Author
  9. name
    Rutkowski P
    type
    Author
  10. name
    Demidov L
    type
    Author
  11. name
    Manikhas GM
    type
    Author
  12. name
    Yan Y
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Gutzmer R
    type
    Author
  2. name
    Stroyakovskiy D
    type
    Author
  3. name
    Gogas H
    type
    Author
  4. name
    Robert C
    type
    Author
  5. name
    Lewis K
    type
    Author
  6. name
    Protsenko S
    type
    Author
  7. name
    Pereira RP
    type
    Author
  8. name
    Eigentler T
    type
    Author
  9. name
    Rutkowski P
    type
    Author
  10. name
    Demidov L
    type
    Author
  11. name
    Manikhas GM
    type
    Author
  12. name
    Yan Y
    type
    Author
bibliography ids
  1. nci-bib-d32187f381d5db06f5cbb27a
book metadata
content sha256
d9813e75bb03087a09cd23caa6d3f2d3a9584d65dd91680f757ee4bf4a5bba8a
document type
citation
dois
  1. 10.1016/S0140-6736(20)30934-X
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:32534646
immutable id
pubmed:32534646@d9813e75bb03087a09cd23caa6d3f2d3a9584d65dd91680f757ee4bf4a5bba8a
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10240
name
Lancet (London, England)
nlm unique id
2985213R
pages
1835-1844
volume
395
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2020 Jun 13;395(10240):1814-1815. doi: 10.1016/S0140-6736(20)31285-X.
    note
    Source null
    related pmid
    32534635
    relationship
    Comment in
  2. citation
    Lancet. 2020 Aug 15;396(10249):466. doi: 10.1016/S0140-6736(20)31721-9.
    note
    Source null
    related pmid
    32798490
    relationship
    Erratum in
outcomes validated
false
pmid
32534646
provenance
batch id
40d9eae1f1d369f13109
provider
NCBI PubMed ESummary
record sha256
e8669f200410d14231b8191344d3aecaab5009052dfadb3ab3d4b928f8dac851
response sha256
03fa1567b6babd78281d8ec4529596b9d4953c2c4ac23257dca371d609645ba9
retrieved at
2026-09-09T23:47:52.637547+00:00
publication date
display
2020 Jun 13
precision
day
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32534646/
title
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.

Preserved source evidence · Not medical advice